For a minute, ignore what is standard, and use your own logic. I'm quite sure one-sided makes sense -- if you look at the distribution of the mean-change.
Do you rule out the possibility that the FDA would grant accelerated approval, with your one additional large study being designated a confirmatory trial, because A 273 appears to be active with super responders, and safer than the amyloid drugs, in a complex illness that has a great unmet need for beneficial drugs?
Market Data 
Markets 
